美国癌症患者越来越多地前往中国或进口中国研发的药品，以获得在美国无法获得或被推迟的尖端治疗。
U.S. Patients Seek Advanced Cancer Therapies in China Amid Regulatory Lags and Biotech Rivalry American cancer patients are increasingly traveling to China or importing Chinese-developed pharmaceuticals to access cutting-edge treatments unavailable or delayed in the United States.
疫情后中国进行国内监管改革，2025年中国占全球新测试药物的比例高达46%，在快速早期临床试验和CAR-T疗法方面表现突出。
Following domestic regulatory overhauls after the pandemic, China accounted for up to 46% of newly tested global drugs in 2025, excelling in rapid early-stage clinical trials and CAR-T therapies.
阿斯利康等全球制药公司与中国开发商如迪哲医药合作，而美国政策制定者对国家健康安全和临床试验外包表示担忧。
While global pharmaceutical companies such as AstraZeneca partner with Chinese developers like Dizal Pharmaceutical, U.S. policymakers express concern over national health security and clinical trial offshoring.
作为回应，美国食品药品监督管理局启动了“试验先锋行动”以加快国内试验时间表，与此同时立法者寻求加强对跨境生物技术交易的监管。
In response, the U.S. Food and Drug Administration initiated Operation TrialBlazer to accelerate domestic trial timelines, even as lawmakers seek tighter oversight on cross-border biotechnology transactions.